KDM4B and neuroblastoma: The H3K9 demethylase, KDM4, has shown promise as a therapeutic target due to the discovery that KDM4B knockout in MYC-driven neuroblastoma cells resulted in downregulation of important MYC target genes, such as MIR17HG, CDC25A, SOX2, KITLG, VCAN, and SDC1 [44].